
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc is progressing positively in its drug development initiatives, particularly with its lead candidate, rhenium (186Re) obisbemeda, which targets central nervous system cancers, alongside advancements in the CNSide CSF assay platform. The company has secured a significant $18 million grant from the Cancer Prevention and Research Institute of Texas to study leptomeningeal metastases, highlighting its potential for funding and growth in this critical area of oncology. Additionally, expanded laboratory licenses for its CNSide Diagnostics in various states and operational enhancements are set to facilitate increased test volumes and adoption, further strengthening Plus Therapeutics' strategic positioning in the CNS oncology market.
Bears say
Plus Therapeutics Inc faces several fundamental risks that contribute to a negative outlook on its stock. Key concerns include the potential failure of its product candidates, particularly rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials, which may hinder future regulatory approvals and commercial viability. Additionally, challenges related to obtaining suitable reimbursement and increasing competition in the pharmaceutical sector further exacerbate the uncertain outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares